Corpus Intelligence IC Memo — LOWELL GENERAL HOSPITAL 2026-04-26 09:06 UTC
IC Memo — LOWELL GENERAL HOSPITAL
Investment Committee Memorandum | MA | 390 beds | Grade C | EBITDA uplift $33.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LOWELL GENERAL HOSPITAL

CCN 220063 | nan, MA | 390 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LOWELL GENERAL HOSPITAL is a 390-bed suburban community hospital in nan, MA with $456.0M in net patient revenue and a -29.1% operating margin. The hospital serves a payer mix of 33.5% Medicare, 12.0% Medicaid, and 54.5% commercial.

Thesis: Undervalued. Our ML models identify $33.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -29.1% to -21.7% (+736bps).

Net Revenue HCRIS$456.0M
Current EBITDA COMPUTED$-132.5M
Operating Margin COMPUTED-29.1%
Occupancy HCRIS62.4%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS34.6%
Distress Probability ML49.0%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
25
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -29.1% places it below the state median. Among 25 size-comparable peers (195-780 beds), the median margin is -14.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (195-780), prioritizing same-state peers. 25 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LOWELL GENERAL HOSPITAL (Target)MA390$456.0M-29.1%
UMASS MEMORIAL MEDICAL CENTERMA657$1.90B-23.6%
BETH ISRAEL DEACONESS MEDICAL MA705$1.67B-38.9%
CHILDRENS HOSPITAL CORPORATIONMA485$1.59B-27.2%
BAYSTATE MEDICAL CENTERMA728$1.46B-15.0%
BOSTON MEDICAL CENTERMA440$1.19B-50.0%
LAHEY CLINIC HOSPITAL INC.MA345$991.1M-4.2%
SOUTHCOAST HOSPITALS GROUP INMA641$845.4M-16.0%
TUFTS MEDICAL CENTERMA385$819.5M-49.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $33.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$9.6M+210bp18mo
Cost to Collect4.5%2.5%$9.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.5M+122bp9mo
Clean Claim Rate88.0%96.0%$292K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$9.6M
Cost to Collect
$9.1M
Denial Rate Reduction
$9.0M
A/R Days Reduction
$5.5M
Clean Claim Rate
$292K
Total EBITDA Uplift$33.6M
Current EBITDA$-132.5M
+ RCM Uplift+$33.6M
Pro Forma EBITDA$-99.0M
Current Margin-29.1%
Pro Forma Margin-21.7%
WC Released (1x)$17.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-203.9M$-538.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-203.9M$-658.6M0.00x-100.0%
Bull Case9.0x11.0x$-183.5M$-614.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-183.5M$-724.1M0.00x-100.0%
Bear Case11.0x10.0x$-224.3M$-640.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-224.3M$-777.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 25 hospitals with 195-780 beds
  • Same-state prioritization (n=26)
  • Comp margins: P25=-26.3% / P50=-14.0% / P75=-4.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.